(1.23%) 5 126.32 points
(1.17%) 38 674 points
(1.94%) 16 149 points
(-1.05%) $78.12
(5.45%) $2.15
(-0.01%) $2 309.30
(-0.34%) $26.74
(0.22%) $964.70
(-0.35%) $0.929
(-1.12%) $10.87
(-0.13%) $0.797
(0.38%) $91.47
4 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 7.74%
8.56% $ 0.890
Live Chart Being Loaded With Signals
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology...
Stats | |
---|---|
Dzisiejszy wolumen | 107 806 |
Średni wolumen | 101 309 |
Kapitalizacja rynkowa | 48.32M |
EPS | $0 ( 2024-03-14 ) |
Następna data zysków | ( $-0.120 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.390 |
ATR14 | $0.00600 (0.67%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Jones Edward Raymond | Buy | 22 000 | Stock Option (Right to Buy) |
2024-04-02 | Deliargyris Efthymios | Buy | 61 000 | Common Stock |
2024-04-02 | Deliargyris Efthymios | Buy | 86 000 | Stock Option (Right to Buy) |
2024-04-02 | Sobel Alan D. | Buy | 22 000 | Stock Option (Right to Buy) |
2024-04-02 | Bloch Kathleen P. | Buy | 65 000 | Common Stock |
INSIDER POWER |
---|
77.68 |
Last 100 transactions |
Buy: 4 191 625 | Sell: 429 500 |
Wolumen Korelacja
Cytosorbents Corp Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
PRQR | 0.959 |
KIN | 0.958 |
SRRA | 0.949 |
NLSP | 0.947 |
BTWNU | 0.943 |
PROF | 0.941 |
GENQ | 0.94 |
ALXN | 0.939 |
RILYH | 0.938 |
IDCC | 0.932 |
10 Najbardziej negatywne korelacje | |
---|---|
ZENV | -0.95 |
GRIN | -0.949 |
UTME | -0.948 |
NCBS | -0.945 |
THMA | -0.942 |
PDBC | -0.939 |
RIVN | -0.938 |
SNPX | -0.934 |
SOPA | -0.93 |
NAKD | -0.928 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Cytosorbents Corp Korelacja - Waluta/Towar
Cytosorbents Corp Finanse
Annual | 2023 |
Przychody: | $36.35M |
Zysk brutto: | $22.39M (61.60 %) |
EPS: | $-0.640 |
FY | 2023 |
Przychody: | $36.35M |
Zysk brutto: | $22.39M (61.60 %) |
EPS: | $-0.640 |
FY | 2022 |
Przychody: | $29.36M |
Zysk brutto: | $15.40M (52.47 %) |
EPS: | $-0.750 |
FY | 2021 |
Przychody: | $43.17M |
Zysk brutto: | $32.12M (74.41 %) |
EPS: | $-0.570 |
Financial Reports:
No articles found.
Cytosorbents Corp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej